Brief: Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue
30/04/2025 12:26
April 30 (Reuters) - Surmodics Inc SRDX.O: SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY Further company coverage: SRDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SurModics
See all newsU.S. STOCKS ON THE MOVE-Surmodics, Cheniere Energy, American Public Education
U.S. STOCKS ON THE MOVE-Surmodics, Energy stocks, American Public Education
Surmodics jumps after US judge rejects FTC's bid to block acquisition by GTCR
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions